The upregulation of activated urokinase-type plasminogen activator (uPA), ultimately leading to the proteolytic degradation of the extracellular matrix (ECM), is a key biological process that drives tumour cell motility and progression towards the characteristic invasive phenotype observed in metastatic cancers [26,27]. This evidence concerns the gene PLAU and metastatic malignant neoplasm.